Trafalgar International (GCAN) Total Non-Current Liabilities (2016 - 2021)
Greater Cannabis Company (GCAN) posted quarterly Total Non-Current Liabilities of $460651.0 for Q1 2021, down 53.71% year-over-year from $995119.0 in Q1 2020, and up 4.11% quarter-over-quarter from $442467.0 in Q4 2020.
Trafalgar International (GCAN) Total Non-Current Liabilities (2016 - 2021) Analysis & Trends
Greater Cannabis Company's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $460651.0 for Q1 2021.
- In Q1 2021, Total Non-Current Liabilities fell 53.71% year-over-year to $460651.0; the TTM figure through Mar 2021 stood at $460651.0 (down 53.71% YoY), while the FY2020 annual figure was $442467.0, down 72.03% from the prior year.
- Total Non-Current Liabilities for Q1 2021 stood at $460651.0, up from $442467.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.6 million in Q4 2019, with the low at -$205403.0 in Q4 2017.
- The 5-year median for Total Non-Current Liabilities is $459956.0 (2019), against an average of $517437.2.
- The sharpest annual moves came in 2017 and 2018: Total Non-Current Liabilities plunged 2437.31% in 2017, then soared 394.54% in 2018.
- Greater Cannabis Company's Total Non-Current Liabilities stood at -$205403.0 in 2017, then soared by 394.54% to $604999.0 in 2018, then soared by 161.46% to $1.6 million in 2019, then tumbled by 72.03% to $442467.0 in 2020, then rose by 4.11% to $460651.0 in 2021.
- Business Quant data shows GCAN's Total Non-Current Liabilities at $460651.0 in Q1 2021, $442467.0 in Q4 2020, and $599261.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 334.00 Mn |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 460,651.00 |
| Dec 31, 2020 | 442,467.00 |
| Sep 30, 2020 | 599,261.00 |
| Jun 30, 2020 | 774,453.00 |
| Mar 31, 2020 | 995,119.00 |
| Dec 31, 2019 | 1.58 Mn |
| Sep 30, 2019 | 508,947.00 |
| Jun 30, 2019 | 459,956.00 |
| Mar 31, 2019 | 409,882.00 |
| Dec 31, 2018 | 604,999.00 |
| Sep 30, 2018 | 401,874.00 |
| Jun 30, 2018 | 274,624.00 |
| Mar 31, 2018 | 217,776.00 |
| Dec 31, 2017 | -205,403.00 |
| Sep 30, 2017 | 235,097.00 |
| Dec 31, 2016 | 8,788.00 |